Amgen quarterly profit slips, obesity data on track for late 2024

Go back to Amgen quarterly profit slips, obesity data on track for late 2024

Amgen (AMGN) PT Raised to $362 at RBC Capital

August 7, 2024 6:26 AM EDT

RBC Capital analyst Gregory Renza raised the price target on Amgen (NASDAQ: AMGN) to $362.00 (from $332.00) while maintaining a Outperform rating.

The analyst comments "MariTide and the obesity portfolio continue to dominate the narrative following the recent "encouraging" interim data look amidst the... More